Despite increased emphasis on evidence based practice in recent years a gap remains between evidence and practice, particularly in resource poor countries. Few studies to date have examined the use of knowledge translation strategies to improve health care outcomes in low income countries. However, given that the majority of health care in these settings is provided by workers with less training and limited resources, the theoretical potential for knowledge translation strategies to improve health care delivery and outcomes by integrating best evidence into routine practice may be greatest in these settings.. Knowledge translation (KT) is an approach to changing health care provider behavior to reduce the gap between evidence and practice in health care delivery. There has been a tendency for knowledge translation interventions to employ generic, off the shelf, strategies, and apply them to deal with specific issues. This generic approach, fails to recognize the variability in the specific ...
Despite increased emphasis on evidence based practice in recent years a gap remains between evidence and practice, particularly in resource poor countries. Few studies to date have examined the use of knowledge translation strategies to improve health care outcomes in low income countries. However, given that the majority of health care in these settings is provided by workers with less training and limited resources, the theoretical potential for knowledge translation strategies to improve health care delivery and outcomes by integrating best evidence into routine practice may be greatest in these settings.. Knowledge translation (KT) is an approach to changing health care provider behavior to reduce the gap between evidence and practice in health care delivery. There has been a tendency for knowledge translation interventions to employ generic, off the shelf, strategies, and apply them to deal with specific issues. This generic approach, fails to recognize the variability in the specific ...
An intensive, week-long introduction to translational cancer research - including cancer medicine, the clinical cancer research environment and collaborative team science - for basic scientists who are predoctoral students and postdoctoral fellows, early-career scientists and senior scientists in transition to translational research. This workshop is hosted in close collaboration with the Dana-Farber Cancer Institute/Harvard Cancer Center, comprised of Beth Israel Deaconess Medical Center, Brigham and Womens Hospital, Childrens Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health and Massachusetts General Hospital.. The Translational Cancer Research for Basic Scientists Workshop will provide basic research scientists with a better understanding of translational research, teach them how to adapt their research for maximum clinical impact and help them transition into a new career in translational cancer medicine. This innovative workshop ...
Translational Cancer Research publishes the results of novel research investigations including risk assessment, cellular and prevention, detection, diagnosis and treatment of human cancers.
The Translational Cancer Research for Basic Scientists Workshop will provide basic research scientists with a better understanding of translational research, teach them how to adapt their research for maximum clinical impact, and help them transition into a new career in translational cancer medicine. This innovative workshop addresses many aspects of translational research including leading multidisciplinary teams, working collaboratively and effectively with industry partners, recognizing the unique needs and environment of the clinic and clinical laboratories, dealing with the regulatory and compliance issues in translational science, and understanding the perspective of the patient in order to place research questions into a broader context. During the course of the week, attendees will gain perspective and background knowledge of the disease from translational scientists in academia and industry, clinicians, and patients, while learning about the latest methods and approaches in ...
Clinical and translational medicine plays a unique and critical role in fostering the flow of bidirectional information between basic and clinical scientists, optimizing new biotechnologies, improving clinical application of new therapeutic concepts, and ultimately improving the quality of life for patients. The term "Clinical and Translational Medicine" (CMT) is defined here as "clinical potential and application of translational research and science to improve the understanding of mechanisms and therapies of human diseases", a new and important concept for the development of disease-specific biomarkers and therapeutic strategies to monitor and cure disease. Clinical and Translational Medicine as an international open-access journal publish articles focused on novel advances in clinical, translational, and clinically-relevant basic science, to accelerate the transition from preclinical research to clinical applications and the communication between basic and clinical scientists. Clinical and ...
Although treatment success rates were higher in both intervention arms than in the control and highest in the PALM PLUS and LHW intervention group, the differences did not reach statistical significance. While this may represent a true finding, a number of other factors may be responsible for our failure to detect a significant effect of the intervention.. First, the lack of a significant difference may be an artefact as our projected sample size was not attained due to the loss of four health centers and decreased TB case notification rate during the trial period. The resultant loss of statistical power may have reduced our ability to detect an effect of the intervention. Second, it is possible that the trials pragmatic design contributed to the lack of effectiveness where a more intensively supported program may have been more successful. However, a heavily supported program would not be feasible in the resource-constrained Malawi health care system. Third, it is possible that a significant ...
Centre for Translational Cancer Research news archive, read more news stories about cancer research by our researchers and colleagues at the University of Otago.
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.theTCR.org) is an Open Access, peer-reviewed journal, published by Pioneer Bioscience Publishing Company (PBPC), publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients.
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.theTCR.org) is an Open Access, peer-reviewed journal, published by Pioneer Bioscience Publishing Company (PBPC), publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients.
|p||i|Clinical and Translational Medicine|/i| plays an important and recognized role in reporting knowledge that contributes towards the understanding of molecular mechanisms of disease. |i|Clinical and Translational Medicine|/i| aims to foster a predictive, preventive, personalized and practical approach towards precision medicine, leading to improved patient prognosis. The journal provides a forum for exchange of ideas between basic and clinical scientists on molecular and cellular mechanisms of disease and potential therapies.|/p||p|The journal covers all areas of clinical and translational medicine but also has several special sections:|/p||ul||li|Clinical and translational cardiovascular medicine - Edited by Yong-Xiao Wang|/li||li|Clinical biostatistics - Edited by Christian Baumgartner and Xiangdong Wang|/li||li|Clinical genomics - Edited by Olaf A. Bodamer and Gilbert S. Omenn|/li||li|Stem cell therapies Edited by Mariusz Z. Ratajczak|/li||li|Translational respiratory medicine - Edited by Chunxue
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Basic and Translational Research on Decision Making in Aging and Alzheimers Disease (R01 - Clinical Trial Optional) PAR-18-544. NIA
Translational Research on the Mechanism of Water and Electrolyte Movements into the Cell Reviewer and Curator: Larry H. Bernstein, MD, FACP Introduction This article is the first in a three part curation covering work that has great importance to our understanding of hydration and possibly the effects of dehydration in cell physiology, and studied effects on…
NIH Funding Opportunities and Notices in the NIH Guide for Grants and Contracts: Roybal Centers for Translational Research on Aging (P30) RFA-AG-14-004. NIA
Implementation science is the study of methods to promote the adoption and integration of evidence-based practices, interventions and policies into routine health care and public health settings. Implementation research plays an important role in identifying barriers to, and enablers of, effective global health programming and policymaking, and leveraging that knowledge to develop evidence-based innovations in effective delivery approaches.. As outlined in the Centers Strategic Plan, Fogarty aims to support research and research training in implementation science using a distributed approach across its programs. Also, projects coordinated by the Center for Global Health Studies (CGHS) at Fogarty support implementation science research methods and frameworks, and use innovative approaches to supporting implementation science. These projects address a wide variety of critical global health research areas, such as HIV prevention, transmission and treatment; household air pollution; mobile health; ...
This reference work gives a compete overview of the different stages of drug development using a translational approach. The book is structured in different parts, following the different stages in drug development. Almost half of the work is dedicated to core of drug discovery using a translational approach, the identification of appropriate targets and screening methods for the identification of compounds interacting with these targets. The rest of book covers the whole downstream pipeline after the identification of lead compounds, such as bioavailability issues, identification of appropriate drug delivery venues, production and scaling issues and preclinical trials. As has been the case with other works in the encyclopedia, the book is made up of long, comprehensive and authoritative chapters, written by outstanding researchers in the field ...
The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) was founded in 2006 to enhance clinical and translational research across the five University of Massachusetts campuses (Amherst, Boston, Dartmouth, Lowell, UMass Medical School) and our clinical partner, UMass Memorial Health Care. With the receipt of an NIH Clinical and Translational Science Award (CTSA) in 2010, and its successful renewal in 2015, the UMCCTS joined a network of 62 NIH-funded centers collaborating to transform the conduct of clinical and translational research across the U.S. The goals of the UMCCTS are to 1) To accelerate the translation of basic discoveries into practical, cost effective solutions that improve human health; and 2) To develop and support the next generation of leaders in clinical and translational research. This collection showcases publications that are the result of UMCCTS supported research.
The Graduate Program in Molecular and Translational Medicine (GPMTM) at Boston University is an interdepartmental, interdisciplinary program based in the Department of Medicine. The mission of the Molecular and Translational Medicine Program is to provide state-of-the-art didactic and research training that produces PhD and MD/PhD scientists who will become leaders in the field of clinically based research.. The program strives to create research opportunities that take full advantage of the wealth of resources available through clinical reagents,clinical expertise, and diverse patient populations at the Boston University Medical Center. At completion of the program each student will have the training and understanding of biomedical systems required to successfully conduct integrative translational research.. ...
FOX CHASE CANCER CENTER has hired Attila Seyhan, PhD, for the newly created position of Director of Translational Medicine Operations. Dr. Seyhan will work closely with Wafik S. El-Deiry, MD, PhD, FACP, Deputy Cancer Center Director for Translational Research, to manage and promote multiple initiatives, including development of investigator-initiated clinical trials and other translational protocols, protocol writing and manuscript preparation, organization of translational medicine events, support for translational requests for application, and grant preparation and submissions. He also will work with industry to follow through on investigator-initiated basic and translational letters of intent and concepts. This work will involve collaboration with clinicians, scientists, regulatory personnel, administrators, tech transfer office staff, the grants management office, institutional review board, institutional advancement, and external entities. A trained molecular biologist, Dr. Seyhan has more ...
The capabilities being gathered into NCATS will offer researchers unparalleled opportunities for intense focus on the reengineering of the translational process, from initial target identification to first-in-human application of small molecules, biologics, diagnostics, and devices. Taking care to avoid a "top-down" management approach, NCATS will count on the scientific community to conceive highly innovative ideas and propose potential implementation projects. The most promising programs will be funded through NIHs highly respected, peer-reviewed grant- and contract-awarding process. Early discussions with a variety of stakeholders have identified several components of translational science that are ripe for the new scientific approach offered by NCATS and will likely be the subject of early targeted funding opportunities.. Therapeutic target validation. Translational science is awash with newly discovered but unvalidated therapeutic targets. NCATS will support broadly applicable rather than ...
High Throughput Sequencing A Pilot Study By Sameek Roychowdhury Matthew K Iyer Dan R Robinson Robert J Lonigro Yi Mi Wu Xuhong Cao Shanker Kalyana Sundaram Lee Sam O Alejandro Balbin Michael J Quist Terrence Barrette Jessica Everett Javed Siddiqui Lakshmi P Kunju Nora Navone John C Araujo Patricia Troncoso Christopher J Logothetis Jeffrey W Innis David C Smith Christopher D Lao Scott Y Kim J Scott Roberts Stephen B Gruber Kenneth J Pienta Moshe Talpaz Arul M Chinnaiyan Science Translational Medicine 30 Nov 2011 111ra121 The mutations present in advanced cancers can be identified by integrative high throughput sequencing to enable biomarker driven clinical trials and ultimately treatment Editor s Summary Abstract Full Text PDF Editors Choice PPAR for the Course in Type 2 Diabetes By Diane Gesty Palmer Science Translational Medicine 30 Nov 2011 111ec192 Targeting adipocyte specific PPARγ may be a new strategy for treating type 2 diabetes Full Text Genetic Screening to Beat Cancer By Carrie M ...
In order to accomplish these objectives open discussion and cooperation among companies, academic, and other institutions will be increasingly important. For all of these reasons, we have created a new subsection of the Journal of Translational Medicine.. Why should a Subsection of the Journal of Translational Medicine be dedicated to combination strategies? Because we want to stimulate discussion over this hot topic. In recent years, several compounds have been developed to treat a broad number of diseases targeting a specific mechanism. However, vast majority of common diseases are multi-factorial and cannot realistically be controlled by targeting a single or few pathways.. Tuberculosis treatment is a classic example of combination therapy [1]. After the discovery of Streptomycin in 1944, improvement in the effectiveness of therapy was observed with the addition of Isoniazid, the first oral mycobactericidal drug in 1952 and Rifamycins in 1957. The introduction of Rifampicin in 1970 further ...
Summary of Translational Medicine - e-Series A: Cardiovascular Diseases, Volume Four - Part 1 Author and Curator: Larry H Bernstein, MD, FCAP and Curator: Aviva Lev-Ari, PhD, RN Part 1 of Volume 4 in the e-series A: Cardiovascular Diseases and Translational Medicine, provides a foundation for grasping a rapidly developing surging scientific endeavor that…
Annals of Translational Medicine&Epidemiology is an open access journal committed to publish articles in all areas of Translational Medicine&Epidemiology.
Fishpond Australia, Carotenoids and Vitamin A in Translational Medicine (Oxidative Stress and Disease) by Werner Siems (Edited ) Olaf Sommerburg (Edited ). Buy Books online: Carotenoids and Vitamin A in Translational Medicine (Oxidative Stress and Disease), 2013, ISBN 1439855269, Werner Siems (Edited by) Olaf Sommerburg (Edited by)
Mayo Clinic Center for Clinical and Translational Science (CCaTS):Graduates of the Ph.D. track in clinical and translational science.
We support translational studies and cross-disciplinary investigation in epidemiology, behavioral health, clinical trials, and public health. The Core will expand its longitudinal database from the existing clinical cohorts to include neuropsychiatric and neurocognitive assessment of a large well-characterized urban minority patient population. The core assists in the development, design, and performance of studies that transition basic research to the bedside and at the same time foster the transition of clinical observations and hypotheses to the laboratory. This Core further interacts with the International HIV Medicine and Research Core to provide training in advanced HIV care and neurocognitive assessment that can be used at the international site to both improve the quality of patient care and also to perform meaningful neurocognitive assessment that benefits patients as well as the research community.. ...
NIMH held this multidisciplinary workshop to identify major trends, gaps, and opportunities in clinical and basic research on repetitive behavior and resistance to change in autism.
Imaging genomics has increasingly moved towards a GWAS approach, using large-scale collaborations to improve power for the detection of variants with small independent effects [29]. Examples of such consortia include the Enhancing Neuro-imaging through Meta-analysis (ENIGMA) consortium [37], Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium [36], Alzheimers Disease Neuroimaging Initiative (ADNI), IMAGEN, which is focused on adolescents [38], and the Uniform Neuro-Imaging of Virchow-Robin Spaces Enlargement (UNIVRSE) consortium [39]. The growing number of GWAS of brain phenotypes and of neuropsychiatric disorders has, on occasion, lent support to previously reported candidate variants [40], but importantly has identified many new variants of interest [41].. An early study by the ENIGMA consortium consisted of approximately 8000 participants, including healthy controls and cases with psychiatric disorders [42]. This study identified significant associations between ...
Cerebral palsy (CP) is defined as a group of permanent disorders of the development of movement and posture, causing activity limitation, attributed to non-progressive disturbances occurring in the developing fetal or infant brain(1). Lesions to the sensorimotor cortex, subcortical axon tracts and subplate are often implicated, with other motor and non-motor areas frequently also affected. The aetiology is complex and often multifactorial (2); causes include hypoxia(3), stroke(4) , infection(5), trauma and genetic factors(6). By the end of the second trimester, corticospinal axons have invaded the spinal grey matter and thalamic afferents the upper layers of the neocortex (7, 8). These systems undergo activity-dependent development (9, 10). After early brain injury, descending pathways are disrupted, with abnormal development of reflex and corticospinal circuitry (11, 12). Movement abnormalities are initially subtle but develop subsequently (13, 14). Aberrant post-lesional plasticity undoubtedly
Preterm labour continues to be a major contributor to neonatal and infant morbidity. Recent data from the USA indicate that the number of preterm deliveries (including those associated with preterm labour) has risen in the last 20 years by 30%. This increase is despite considerable efforts to introduce new therapies for the prevention and treatment of preterm labour and highlights the need to assess research in this area from a fresh perspective. In this paper we discuss i) the limitations of our knowledge concerning prediction, prevention and treatment of preterm labour and ii) future multidisciplinary strategies for improving our approach.
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder with monogenic mutations setting the stage for successful gene therapy treatment. We have completed a study that directly deals with the following key issues that can be directly adapted to a gene therapy clinical trial using rAAV considering the following criteria: 1) A regional vascular delivery approach that will protect the patient from widespread dissemination of virus; 2) an approach to potentially facilitate safe passage of the virus for efficient skeletal muscle transduction; 3) the use of viral doses to accommodate current limitations imposed by vector production methods; 4) and at the same time, achieve a clinically meaningful outcome by transducing multiple muscles in the lower limb to prolong ambulation. The capacity of AAV1, AAV6 or AAV8 to cross the vascular endothelial barrier carrying a micro-dystrophin cDNA was compared under identical conditions with delivery through a catheter placed in the femoral artery of the mdx
Objectives: Toll like receptor (TLR) signaling emerged as a significant pathway in our whole genome peripheral blood study of ischemic stroke patients. In our dataset, TLR signaling is associated with stroke severity, can predict outcome and is influenced by age. The age-mediated effects on TLR expression and kinase signaling in response to cerebral ischemia are not well-characterized. The objective of this project was to confirm and further characterize our clinical findings in a preclinical aged stroke model by analyzing TLR gene expression and the kinase proteome.. Methods: An SaBiosciences rat TLR PCR array was used to compare brain and blood gene expression in 3 (n=3) and 18 (n=3) month old rats that underwent embolic middle cerebral artery occlusion (MCAO) with tPA reperfusion and sacrificed at 24 hours. Blood samples were collected via femoral artery in Qiagen RNA protect tubes. Rats were perfused and then Brain tissue was collected in RNA later. A Kinetworks Protein Kinase Screen 1.2 was ...
Research funding agencies, industry and academic institutions have placed increased attention to the issue of ensuring research methods and results are reproducible. Irreproducible data poses a danger to the fundamental mission and promise of translational science, and data reproducibility should be considered as integral to the translational research process. This session will present approaches, tools and best practices to integrate data reproducibility and rigor into translational research programs. Additionally, key federal policies and initiatives impacting data quality and rigor will be discussed ...
The Institute for Translational Medicine and Therapeutics (ITMAT) supports research at the interface of basic and clinical research focusing on developing new and safer therapeutics. ITMAT includes faculty, basic research space, and the Clinical and Translational Research Center (CTRC), which derives from the integration of the former General Clinical Research Center (GCRC) of both Penn and the Childrens Hospital of Philadelphia (CHOP). ITMAT also offers research cores, educational programs (including a Masters in Translational Research), and research programs and centers. These are designed to facilitate training and research from proof of concept in cellular and animal model systems across the translational divide to proof of concept and dose selection in humans.
The Institute for Translational Medicine and Therapeutics (ITMAT) supports research at the interface of basic and clinical research focusing on developing new and safer therapeutics. ITMAT includes faculty, basic research space, and the Clinical and Translational Research Center (CTRC), which derives from the integration of the former General Clinical Research Center (GCRC) of both Penn and the Childrens Hospital of Philadelphia (CHOP). ITMAT also offers research cores, educational programs (including a Masters in Translational Research), and research programs and centers. These are designed to facilitate training and research from proof of concept in cellular and animal model systems across the translational divide to proof of concept and dose selection in humans.
The mission statement of the Scripps Translational Science Institute is to innovate, transform, and fully integrate clinical and translational research.
The Parker Institute collaboration is incredibly important," Lynch says. "It brings together leading immunologists from six academic cancer centers in the United States who are focused on translating breakthrough research into I-O treatments that could make a difference for patients." One of the areas that Lynch hopes the collaboration will shed light on is why cold tumors, those that arent recognized by the immune system and thus arent infiltrated with immune cells, dont respond to I-O therapies. "We know that immunotherapies can be very active in some cancers-for example, melanoma, kidney cancer, squamous cell lung cancer and leukemia," he says. "But we need to find out why we cant generate a profound immune response in other cancers, such as estrogen receptor positive breast cancer, or colon cancer, or pancreatic cancer." Established in 2015 through a $250 million grant from The Parker Foundation, The Parker Institute collaboration is a boon for participating organizations. Operating ...
phdthesis{7134a3c6-9b42-4596-bd81-007d9d912cd4, author = {LINDBLAD, OSCAR}, isbn = {978-91-7619-244-3}, language = {eng}, publisher = {Lund University: Faculty of Medicine}, school = {Lund University}, title = {FLT3 and KIT in acute myeloid leukemia. Translational studies on oncogenic signaling from receptor tyrosine kinases. : Translational studies on oncogenic signaling from receptor tyrosine kinases}, url = {https://lup.lub.lu.se/search/ws/files/7593560/FLT3_and_KIT_in_Acute_Myeloid_Leukemia.pdf}, year = {2016 ...
iframe src="https://lup.lub.lu.se/search/organization/v1000559?embed=1&hide_pagination=1&hide_info=1&hide_options=1" ...
For more information on ACTSI, please visit www.actsi.org. Do you have news, seminars, or events of interest to clinical and translational researchers? Send them to [email protected] by noon on Thursday. To suggest subscribers or unsubscribe to the listserv please email [email protected] Please include the following citation in any publications resulting from direct or indirect ACTSI support, "Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." KL2 Scholars should also list KL2 TR000455 and TL1 Trainees should also list TL1 TR000456. ...
The Annals of Translational Medicine (Ann Transl Med; ATM; Print ISSN 2305-5839; Online ISSN 2305-5847) publishes articles that describe new findings in the field of translational research in medicine, provides current and practical information on diagnosis, prevention and clinical investigations of medicine. Specific areas of interest include, but not limited to, multimodality therapy, biomarkers, imaging, biology, pathology, and technical advances related to medicine.
The Annals of Translational Medicine (Ann Transl Med; ATM; Print ISSN 2305-5839; Online ISSN 2305-5847) publishes articles that describe new findings in the field of translational research in medicine, provides current and practical information on diagnosis, prevention and clinical investigations of medicine. Specific areas of interest include, but not limited to, multimodality therapy, biomarkers, imaging, biology, pathology, and technical advances related to medicine.
The Annals of Translational Medicine (Ann Transl Med; ATM; Print ISSN 2305-5839; Online ISSN 2305-5847) publishes articles that describe new findings in the field of translational research in medicine, provides current and practical information on diagnosis, prevention and clinical investigations of medicine. Specific areas of interest include, but not limited to, multimodality therapy, biomarkers, imaging, biology, pathology, and technical advances related to medicine.
The Annals of Translational Medicine (Ann Transl Med; ATM; Print ISSN 2305-5839; Online ISSN 2305-5847) publishes articles that describe new findings in the field of translational research in medicine, provides current and practical information on diagnosis, prevention and clinical investigations of medicine. Specific areas of interest include, but not limited to, multimodality therapy, biomarkers, imaging, biology, pathology, and technical advances related to medicine.
Researchers from Dartmouth-Hitchcock to present data showcasing KAPA Kits ability to assess quantity and quality of FFPE DNA for translational cancer
Translational Medicine research program is removing barriers to multi-disciplinary collaboration, attracts attention of researchers to clinically relevant problems and validates discoveries from molecular target, biomarker and drug discovery pipelines to proof-of concept clinical trials. By enabling physicians, chemistries, and pharmacologists to leverage biology technologies, translation medicine program facilitates early detection of cancer and other diseases, increases efficiency in drug development, improves drug efficacy and enables personalized medicine. The program collects and comparatively analyzes clinical information, including data contained in hospital and/or national registries and medical records, laboratory and imaging reports, etc. The research program supports for clinical trials phase I-III in specific patient populations, including healthy volunteers, pediatric population, disease specific populations, etc. The primary interest is put on proof-of-concept clinical trials phase ...
LIAISON OFFICE RESEARCH COMMITTEE UNIVERSITY OF IOANNINA 1st Post-graduate Symposium on Clinical & Translational Medicine 24 February 2013 FP7 EUROPA ESFESOF Prizes/Awards Other Initiatives
Translational medicine builds on basic research advances - studies of biological processes using cell cultures, for example, or animal models - and uses th
Watch this video to understand how researchers use multiplex immunoassay technology in translational medicine. Information from the labs of Dr Francis Spinale and Dr Steven Kornlau indicate that using the Bio-Plex® suspension array system has the potential to impact on screening and treatment of disease.
By Bin Zheng, Zhixiang Liao, Joseph J. Locascio, Kristen A. Lesniak, Sarah S. Roderick, Marla L. Watt, Aron C. Eklund, Yanli Zhang-James, Peter D. Kim, Michael A. Hauser, Edna Grünblatt, Linda B. Moran, Silvia A. Mandel, Peter Riederer, Renee M. Miller, Howard J. Federoff, Ullrich Wüllner, Spyridon Papapetropoulos, Moussa B. Youdim, Ippolita Cantuti-Castelvetri, Anne B. Young, Jeffery M. Vance, Richard L. Davis, John C. Hedreen, Charles H. Adler, Thomas G. Beach, Manuel B. Graeber, Frank A. Middleton, Jean-Christophe Rochet, Clemens R. Scherzer, the Global PD Gene Expression (GPEX) Consortium. Science Translational Medicine ...
Citation Machine™ helps students and professionals properly credit the information that they use. Cite your journal article in Clinical and Translational Medicine format for free.
... is an open access journal publishing articles focusing on information derived from human experimentation so as to optimise the communication between basic and clinical science.
The University of Massachusetts Center for Clinical and Translational Science (UMCCTS) was founded in 2006 to enhance clinical and translational research across the five University of Massachusetts campuses (Amherst, Boston, Dartmouth, Lowell, UMass Medical School) and our clinical partner, UMass Memorial Health Care. With the receipt of an NIH Clinical and Translational Science Award (CTSA) in 2010, and its successful renewal in 2015, the UMCCTS joined a network of 62 NIH-funded centers collaborating to transform the conduct of clinical and translational research across the U.S. The goals of the UMCCTS are to 1) To accelerate the translation of basic discoveries into practical, cost effective solutions that improve human health; and 2) To develop and support the next generation of leaders in clinical and translational research. This collection showcases publications that are the result of UMCCTS supported research.
The Critical Care Translational Medicine Group designs, oversees and coordinates international trials in acute respiratory distress syndrome (ARDS) and sepsis.
La unidad de INVESTIGACIÓN TRANSLACIONAL EN ENFERMEDADES RENALES Y CARDIOVASCULARES (TRECARD) es un grupo multidisciplinar dedicado al desarrollo de aplicaciones diagnósticas y terapéuticas innovadoras y clínicamente útiles para enfermedades renales y cardiovasculares, principalmente lesión renal aguda, enfermedad renal crónica e hipertensión. Los investigadores de TRECARD pertenecen al Instituto de Investigación Biomédica de Salamanca…
Upcoming Workshop on Knowledge Translation (KT) Basics Presented by: Knowledge Translation Program, St. Michaels Hospital, Toronto, Canada **Deadline to apply is August 18, 2017** Workshop Overview Knowledge translation (KT) is a bridge between research and real-world practice in an effort to strengthen health systems and improve health outcomes. But how do you apply evidence? At the KT Program, we believe that we can implement change in the health system better by thinking about change differently. Our approach to KT is rooted in theory and science, but our application of KT is uniquely pragmatic and focused on real-world impact. Our approach to training involves empowering individuals and organizations in the health system with knowledge and support on how to do KT. Knowledge Translation (KT) Basics is a 2-day workshop on the fundamentals of implementing change using best practices in KT. In KT Basics, participants will learn how to: Identify key KT definitions Assess and prioritize implementation
Translational research describes the continuum from basic science discovery to clinical application-from bench to bedside, or in the case of a newborn with complex CHD, from bench to bassinet. The central tenets of early translational research are delineated by the first goal of the NHLBIs Strategic Plan: "To improve understanding of the molecular and physiological basis of health and disease, and to use that understanding to develop improved approaches to disease diagnosis, treatment, and prevention" (15).. The conventional model for funding translational research has been to create a multidisciplinary team of researchers, typically at a single institution or a few institutions. The expectation was that communication and cooperation between basic scientists and clinical researchers would allow knowledge to flow seamlessly from the laboratory to the clinic and back again. While such an arrangement may have enhanced collaboration between groups that often do not interact, it may have been overly ...
The mission statement of the Scripps Translational Science Institute is to innovate, transform, and fully integrate clinical and translational research.
Applications for the Certificate Program in Clinical and Translational Research will be reviewed by the Clinical and Translational Research Admissions Committee, which is composed of public health faculty and other professionals. Applicants will be assessed on their academic performance as well as evidence of their potential in the field of clinical and translational research. Applications are reviewed on a rolling basis until July 1.. ...
Work carried out in the area of Translational Research is world leading and is informed by current research and the needs of our collaborative partners, to deliver cutting edge technology to the marketplace.. Research in this area is based in the fields of chemical and biological sciences and involves collaboration with a number of industrial and clinical collaborators.. ...
Watch a video about the groundbreaking translational research taking place at the CTRC. CTRC Outpatient Unit Frequently Asked Questions pdf. Fitzgerald Group Ellicott Street, Buffalo NY Click for Map July 11, Times: All coordinators and research assistants new to the CTRC are required to attend a CTRC New User Orientation prior to utilizing the facilities. Gonzalez Convention Center History timeline St. The Clinical Translational Research Center CTRC , formerly the General Clinical Research Center GCRC , provides the resources to perform high quality, patient-oriented research across the Academic Health Center AHC and the community. From June 16, To June 17, Fitzgerald Group Ellicott Street, Buffalo NY Click for Map November 1, Grant. Texas holdem poker king app Serves more than 4. The clinic provides experienced research nurses to assist with protocol implementation. Regulates activation and degradation of trypsinogens and procarboxypeptidases by targeting specific cleavage sites within their ...
The Oregon Clinical & Translational Research Institute (OCTRI) is currently accepting applications for the Catalyst Award, a pilot project program designed to enhance translational research at OHSU. The Catalyst Award is offered in collaboration with the School of Medicines Research Roadmap and the Office of the Senior Vice President for Research. This year, catalyst funds will support the efforts of investigators to develop and disseminate consequential, novel research methodology. The development of new methodologies is … Read More. ...
Boey, C.M. (2010) Reflections on the significance of the relationship between mind and body in medicine. Journal of Health and Translational Medicine, 13 (1). pp. 3-11.. Koh, P.S.; Cha, K.H.; Lucy, C.; Rampal, S.; Yoong, B.K. (2012) Superior somatic pain relief and improved visceral pain control is achieved using pre-emptive analgesia for laparoscopic cholecystectomy: A randomized controlled trial. Journal of Health and Translational Medicine, 15 (2). pp. 1-7. ISSN 1823-7339. Thong, K.L.; Puthucheary, S.D.; Boey, C.C.M.; Pang, T. (1999) Investigation of a recurrent case of Salmonellosis due to Salmonella bovismorbificans and Salmonella matopeni using pulsed-field gel electrophoresis analysis and antibiograms. Journal of Health and Translational Medicine, 4 (2). pp. 104-109. ISSN 1823-7339. ...
Previous data have proven that GRK2 inhibition is protective against chronic heart failure. Inhibition of a protein known to contribute to heart failure also appears to be protective of the heart in more acute cardiac stress injury, namely ischemia reperfusion, according to two studies conducted at the Center for Translational Medicine at Thomas Jefferson University. The studies will be presented at the American Heart Association Scientific Sessions 2009 in Orlando, Fla.. The first study was presented by Henriette Brinks, M.D., a postdoctoral fellow in the Center for Translational Medicine. The researchers, led by Walter J. Koch, Ph.D., director of the Center for Translational Medicine, examined mice that overexpressed the G-Protein coupled Receptor Kinase-2 (GRK2). This overexpression was deleterious in ischemic myocardium, according to Dr. Koch, in that these mice had larger areas of infarction or myocardial death. However, inhibition of GRK2 activity with the peptide GRK2 inhibitor, ï ...
Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award number UL1TR002378. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." KL2 Scholars should also list KL2TR002381 and TL1 Trainees should also list TL1TR002382 ...
|p||i|Implementation Science|/i| publishes research relevant to the scientific study of methods to promote the uptake of research findings into routine healthcare in clinical, organisational or policy contexts.|/p|
Purchase Progress in Molecular Biology and Translational Science, Volume 159 - 1st Edition. Print Book & E-Book. ISBN 9780128162354, 9780128162361
Fingerprint Dive into the research topics where Centre for Healthcare Resilience and Implementation Science is active. These topic labels come from the works of this organisations members. Together they form a unique fingerprint. ...
Three years ago, UCI created the Institute for Clinical and Translational Science (ICTS), which identifies tests, and implements innovative ways to break down b...
If you have problems viewing PDF files, download the latest version of Adobe Reader. For language access assistance, contact the NCATS Public Information Officer. National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966. ...
The School of Clinical Sciences at Monash Health is a vibrant hub of teaching and translational research with a strong collaboration between Monash University and Monash Health, Victorias largest hospital network. SCS sits within the Faculty of Medicine, Nursing and Health Sciences, Monash University, and seeks to provide an innovative approach to research, education, teaching and clinical practice. The school provides a diverse range of specialities and prides itself on being at the forefront of medical, clinical/translational research and education.
The School of Clinical Sciences at Monash Health is a vibrant hub of teaching and translational research with a strong collaboration between Monash University and Monash Health, Victorias largest hospital network. SCS sits within the Faculty of Medicine, Nursing and Health Sciences, Monash University, and seeks to provide an innovative approach to research, education, teaching and clinical practice. The school provides a diverse range of specialities and prides itself on being at the forefront of medical, clinical/translational research and education.
Planning to study in ? All information about Implementation Science in Health Care in Nijmegen: admission deadlines and requirements and grants
The Mechanisms of Disease and Translational Science PhD Training Track (MoD) at the UT Southwestern Graduate School will train an elite group of PhD students to...
Professor Robyn OHehir has been a key international figure in allergy and asthma research and clinical care for over 25 years. She is an academic clinician scientist who successfully combines a strong track record in basic research with a clear commitment to clinical medicine, in this way demonstrating the value of translational medical research. The contribution of Professor OHehir to the allergy and respiratory field ranges from basic animal studies on the immunology of allergy and T cell epitope mapping, through translational research on novel immunogens designed to invoke protective immunity, to clinical research on the pathophysiology and management of asthma. She has more than 200 publications. The importance of her research is reflected by her success in competitive grant funding with an annual personal research budget in excess of $1.5 million. This includes continuous NHMRC funding (including 21 NHMRC or ARC grants over her career at Monash/Alfred since 1997) and a Co-operative ...
Several unique features of the centre will facilitate realisation of the integrative and translational approach; these include a cross-disciplinary and highly collaborative scientific environment within the zmfu (Centre of Musculoskeletal Research Ulm), the Clinical Research Unit KFO200 and the Trans-regional Research Unit 793, and the long-standing commitment of the Medical Faculty at Ulm University to cutting-edge basic, (re)translational, and clinical research in trauma. These attributes are complemented by sophisticated, clinically relevant in vitro and in vivo models of the trauma impact and resulting complications to gain deep insights into the mechanistic complexity and regeneration potential post trauma as well as to evaluate innovative cell- and molecular based therapies. As compelling scientific and clinical challenges, central hypotheses are defined in the CRC, proposing to: A) better understand the danger response after trauma on a molecular, cellular, organ, and organism level; B) ...
On January 17-18, 2010, the American Association for Cancer Research (AACR) hosted a Think Tank meeting in San Francisco that brought together a group of clinical and translational research thought leaders to identify the most promising scientific priorities and opportunities for the future of this field. This meeting was held over 2 days and included specific presentations on key areas such as animal models; the impact of genomics on personalized cancer therapy; innovative clinical trial design; imaging strategies, controversies, and opportunities; and biomarkers and companion diagnostics. Breakout sessions focused on research, information sharing, standardization, validation, regulatory issues, and education. The overall goal of this gathering was to provide a forum for thoughtful input and discussion about the strategies needed to help catalyze progress in the field of clinical and translational cancer research.. A number of key issues were discussed over this 2-day period, and several ...
To answer these questions, we use neurocognitive assessments and various magnetic resonance imaging (MRI) techniques, including structural MRI, functional MRI (fMRI), resting-state functional connectivity (rs-fcMRI), and Diffusion Tensor Imaging (DTI). Whenever possible, we aim to take a translational approach to behavioral neuroscience, including remaining well-informed about basic science and implementing behavioral methods that may be easily linked between humans and animal models ...
Hypertension-Induced End-Organ Damage Dominik N. Müller & Ralf Dechend (ECRC group). Summary:. Hypertension is the primary risk factor for cardiovascular disease, the major cause of death worldwide. The groups major research interests are the renin-angiotensin system (RAS), the immune system and how both systems cause hypertension-induced target organ damage. In a translational approach, the Müller/Dechend lab focuses on the vessels, hearts, kidneys and the uteroplacental units. Our recent work has extended these concepts and we are now undertaking projects to analyze how epigenetic factors, such as high salt, influence immune cells and target organ damage.. The group cooperates closely with MDC and Charité scientists, as well with several national and international collaborators. The group has also been a resource for young clinicians and doctoral students beginning their careers in experimental cardiovascular research. In 2011, Dominik N. Müller received a professorship for Experimental ...
After receiving a master degree in Biotechnology at the University of Verona (Italy) in 1998, I joined the neuroscience centre of GlaxoSmithKline (GSK), a large research-based pharmaceutical company based in Verona (Italy) and Harlow (UK), where I pioneered the use of functional magnetic resonance imaging (MRI) to describe the neural substrates modulated by pharmacological agents, a line of research that I also pursued to obtain a PhD degree in biomedical imaging with the University of Verona.. During my years at GSK I took on roles of increasing responsibility, and developed a strong background in MRI, image processing and analysis, as well as in the application of translational approaches to study neuropsychiatric brain disorders.. In 2010 I joined the Istituto Italiano di Tecnologia, where I lead the Functional Neuroimaging Laboratory. The lab is equipped with a 4-channel 7 Tesla MRI scanner for in vivo imaging. During my research activity, I have described the circuital substrates modulated ...
The Namur Thrombosis & Hemostasis Center (NTHC) aims at gathering knowledge in thrombosis and hemostasis in the field of basic and clinical research, with a translational approach. It builds on synergy between the Pharmacy Department of the UNamur and different clinical disciplines involved in the management of thrombotic diseases from the CHU UCL Namur.
The origin of the epidemic of IgE-associated (allergic) diseases is unclear. MeDALL (Mechanisms of the Development of ALLergy), an FP7 European Union project (No. 264357), aims to generate novel knowledge on the mechanisms of initiation of allergy and to propose early diagnosis, prevention, and targets for therapy. A novel phenotype definition and an integrative translational approach are needed to understand how a network of molecular and environmental factors can lead to complex allergic diseases. A novel, stepwise, large-scale, and integrative approach will be led by a network of complementary experts in allergy, epidemiology, allergen biochemistry, immunology, molecular biology, epigenetics, functional genomics, bioinformatics, computational and systems biology. The following steps are proposed: (i) Identification of classical and novel phenotypes in existing birth cohorts; (ii) Building discovery of the relevant mechanisms in IgE-associated allergic diseases in existing longitudinal ...
This article is part of a multi-part CME-certified activity titled Translational Therapeutics at the Platelet Vascular Interface. In order to achieve all of the activitys learning objectives, please read all of the components of the activity listed in the Table of Contents and follow the "Instructions for Participation and Obtaining CME Credit" outlined prior to the Introduction.. This meeting illustrates the power of an integrated translational approach to interrogation of the platelet-vascular interface. Increasingly, the technologies and investigations of drug response in cells, model systems, and humans, described by distinct investigators at this meeting, will be integrated by single research groups. We are only beginning to understand that manipulations of a single signaling pathway in a cell may perturb a complex and interdependent system of informational processing. Already, such biological systems paradigms are being exploited in the process of drug discovery. Perhaps it is time for a ...
Here, we applied an interdisciplinary, translational approach in rodents and humans to discover and characterize a new family of endogenous lipid mediators of pain and itch. On the basis of our own findings and previous reports indicating that the skin is enriched in both linoleic acid and enzymes capable of peroxidation and hydroperoxide isomerization, we predicted that the skin would have high concentrations of four previously unknown endogenous 11-hydroxy-trans-epoxy- or 11-keto-trans-epoxy-octadecenoates and four previously identified 9- or 13-hydroxy- or 9- or 13-keto-trans-epoxy-octadecenoates. As predicted, we measured substantial concentrations of 11H-12,13E-LA, 11H-9,10E-LA, 11K-12,13E-LA, and 11K-9,10E-LA in human skin. Notably, 11H-12,13E-LA was increased in inflamed psoriatic human skin, sensitized primary afferent DRG neurons in ex vivo CGRP release assays, and induced C-fiber-mediated pain-related hypersensitivity in rats. Moreover, plasma 11H-12,13E-LA correlated with headache ...
The simulation of the virtual epileptic patient is presented as an example of advanced brain simulation as a translational approach to deliver improved results in clinics. The fundamentals of epilepsy are explained. On this basis, the concept of epilepsy simulation is developed. By using an iPython notebook, the detailed process of this approach is explained step by step. In the end, you are able to perform simple epilepsy simulations your own. ...
The simulation of the virtual epileptic patient is presented as an example of advanced brain simulation as a translational approach to deliver improved results in clinics. The fundamentals of epilepsy are explained. On this basis, the concept of epilepsy simulation is developed. By using an iPython notebook, the detailed process of this approach is explained step by step. In the end, you are able to perform simple epilepsy simulations your own. ...
Background: Oestradiol has a protective effect on coronary artery health in women but the effect it has on men, is controversial. A translational approach was followed to assess whether sex hormone levels are associated ...
EU-LIFE JOINT COURSE 6th Building Bridges Symposium: Epigenetics in Clinical and Translational Research October 10-11, 2017 Biomedicum Helsinki, Finland The Building Bridges symposia series is arranged to bridge clinical and basic/translational research and provide examples of how teams of investigators are working together towards a better understanding of the pathophysiology of disease and improved options for patient treatment and care.
EU-LIFE JOINT COURSE 6th Building Bridges Symposium: Epigenetics in Clinical and Translational Research October 10-11, 2017 Biomedicum Helsinki, Finland The Building Bridges symposia series is arranged to bridge clinical and basic/translational research and provide examples of how teams of investigators are working together towards a better understanding of the pathophysiology of disease and improved options for patient treatment and care.
The 103 research staff at SBRI are organized in 8 teams and 1 clinical/translational research platform (StemGamE). The main research axes are stem cell biology, and integrative and cognitive neuroscience.. There are strong continuities between teams, which not only share technical approaches, but also common scientific objectives. SBRI brings together cutting-edge experimental techniques and advanced technology to seek out an in-depth understanding of primate specific features at the molecular, cell and system level.. The quality of SBRI activities has been acknowledged by excellent levels of international (UE, HFSP) funding as well as by PALSE/IdeX start-up grants.. The recently awarded funds from "Investissements dAvenir" INGESTEM program have significantly contributed to the improvement and development of SBRI infrastructure. SBRI teams are members of the "Laboratoire dexcellence (Labex)"entitled "CORTEX", headed by Henry Kennedy, and of the "LabEX DEVweCAN"(headed by P. Mehlen and bringing ...
The Medical Bioinformatics team at Nemours supports ACCEL funded research through the BERD core and via collaborations with research scientists within the network. Our team has developed both the wet-bench applications and bioinformatic pipelines for conducting next generation sequencing (NGS), with the goal of identifying relevant biological insights for complex clinical translational research projects. The team has a state-of-the-art sequencing machine, NextSeq, and a robust computational infrastructure that includes a high-performance computing (HPC) cluster consisting of both both a GPU and CPU powered nodes. Our team focuses on training and education such that PIs have a clear understanding of these analyses from start to finish. Some of our pipelines include industry standards such as GATK Best Practices for germline variant discovery in whole-genome sequencing (WGS). This is a tried and tested analysis standardized by the Broad Institute which allows for the discovery of high-confidence ...
GermanCancer Research Center: Largest biomedical research institute in Germany. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is the largest biomedical research institute in Germany. More than 3,000 staff members, including 1,000 scientists, are investigating the mechanisms of cancer and are working to identify cancer risk factors. They provide the foundations for developing novel approaches in the prevention, diagnosis, and treatment of cancer. The DKFZ is a member of the Helmholtz Association of National Research Centers.. In 2003, DKFZ, Heidelberg University Medical Center, and Heidelberg Thorax Clinik together established Germanys first comprehensive Cancer Center: The National Center for Tumor Diseases (NCT) Heidelberg was launched with the mission of combining optimized interdisciplinary patient care with excellence in translational cancer research.. Within the National Consortium for Cancer Research, DKFZ acts as the nationwide hub for excellent partners from ...
The Biomedical Imaging Lab conducts translational research using imaging to investigate pathophysiology and function. One overarching focus of our research is the investigation of brain-body interactions through imaging. In particular, we are studying the interactions between the central and peripheral nervous system and the musculoskeletal system in a number of clinical conditions of major public health significance, such as chronic pain, stroke, spinal cord injury, and amputation. The interdisciplinary group conducts pre-clinical research for developing new technology as well as translational research on human subjects. The group uses state-of-the-art ultrasound and laser instrumentation for developing new ultrasound, optical, and hybrid imaging techniques. Our research has potential applications in noninvasive diagnosis, screening, and treatment monitoring for a number of diseases, as well as for understanding underlying mechanisms of disease.. Ongoing research is being conducted in three ...
See how researchers are using CyTOF systems to answer questions that were inconceivable before the advent of mass cytometry. In addition to cell type discoveries and functional profiling, several publications present new methods in high-dimensional data analysis and sample barcoding. CyTOF technology has played a key role in dozens of publications in areas such as immunology, cancer research, drug discovery, vaccines, stem cells and clinical translational research. View Publications ...
As we elucidate cancer biology, it has become increasingly clear that growth factor or cytokine receptors and/or their intracellular second messengers can provide attractive new targets for novel cancer therapeutics. Indeed, a vast new array of small molecule inhibitors that target growth factor or cytokine receptors and/or their intracellular signalling pathways are in pre-clinical and clinical development. Understanding the target biology, how these agents act and how they will integrate into clinical practice is vital for both scientists and clinicians working in translational cancer research. Consequently, this meeting will bring together scientists and clinicians who are either working on or are interested in learning about cell signalling in cancer therapeutics. Key speakers from across North America and Europe who work in both university and pharmaceutical backgrounds will provide the latest information in this hot area of new science. Our two day international meeting will have sessions ...
There are over 100 tumor types only in the central nervous system. The Translational Cancer Research Group at the Department of Biomedicine provided data and material for a new diagnostic tool that will make it easier for cancer researchers to see the difference.
Winship names head. Jonathan Simons, director of the Molecular Pharmacology Program and Cancer Gene Therapy Laboratory at the Johns Hopkins University School of Medicine, has been named director of the Winship Cancer Institute effective Feb. 1.. A highly acclaimed physician-scientist in translational cancer research, Simons is the first investigator to successfully use human gene therapy to create clinically measurable immune responses against metastatic prostate cancer. Simons, 41, an associate professor of oncology and urology at Hopkins, is internationally recognized as a leader in the molecular oncology and gene therapy of prostate cancer.. This is an enormously important appointment for Emory, said Thomas Lawley, dean of the School of Medicine. The Winship Cancer Institute has not yet realized its great potential. But it stands poised to become one of the nations top centers for cancer care, research, prevention and education, and we have found a director with the vision, energy and ...
I have a long-standing interest in the field of clinical and translational cancer research and I have been involved in several (more than 50) clinical trials as principal or sub-investigator. Since 2009 I focused my activity in early-phase clinical development of anticancer new drugs (molecular targeted agents; immunotherapeutics agents) inside the clinical Pharmacology Unit, being responsible for the clinical management of the all the phase I studies conducted at the Humanitas Cancer Center.. Since 2014 I became Head of Neuroncology at the Humanitas Cancer Center, being part of the Multidisciplinary Neurongologic Team and conducting clinical trials with new immunotherapeutic agents. Im principal investigator of several translational projects in the field of Neuroncology and Immuno-Neuroncology aimed to find prognostic or predictive biomarkers for the clinical management of patients with brain tumors.. My principle fields of research interest are:. ...
Our research lies at the interface of basic and translational cancer research. We ask how different combinations of genetic mutations in tumour suppressor and oncogenic signalling pathways affect the behaviours of tumours and their responses to therapies. We employ a variety of genetic approaches to tackle these questions, with current major research interests in kidney tumours and different types of sarcomas. In addition to the use of conventional mouse genetics, we develop new tools that allow more rapid genetic approaches in mice with the aim of being able to more efficiently and rapidly investigate the combined effects of genetic alterations in multiple signalling pathways on tumour cells as well as on their interaction with the tumour microenvironment. We utilise both genetic and chemical library screening approaches to identify therapeutic sensitivities based on the mutational spectrum of tumours and conduct pre-clinical tests of molecularly-targeted agents using our mouse models. We work ...